Business Context and Reporting Period
This Form 8-K was filed by Trovagene, Inc. on February 6, 2015. The filing reports the entry into a Material Definitive Agreement regarding a public offering of common stock. Note: The request metadata references "Cardiff Oncology, Inc.," but the filing text explicitly identifies the registrant as Trovagene, Inc.
Key Financial Metrics and Transaction Details
- Transaction Type: Public offering of common stock.
- Shares Issued: 4,444,444 shares of Common Stock.
- Offering Price: $4.50 per share.
- Expected Net Proceeds: Approximately $18.3 million (after underwriting discounts, commissions, and estimated offering expenses).
- Over-Allotment Option: Underwriters have a 30-day option to purchase up to an additional 666,666 shares.
- Expected Closing Date: On or about February 11, 2015.
- Lock-Up Period: Company, directors, and officers are restricted from selling shares for 90 days post-closing without consent.
Material Changes
The filing does not provide comparative financial data (revenue, profit, cash flow, or margins) as it is a current report regarding a specific corporate event rather than a periodic financial statement. The primary material change is the anticipated increase in liquidity through the issuance of new equity.
Outlook, Risks, and Management Commentary
- Forward-Looking Statements: The company notes that actual results may differ materially from expectations regarding the settlement of the sale and receipt of proceeds.
- Risks: Key risks include the ability to satisfy applicable closing conditions under the Purchase Agreement. Additional risk factors are disclosed in the accompanying prospectus supplement and SEC reports.
- Management Action: A press release was issued on February 6, 2015, announcing the pricing of the offering.
Investor Verification Checklist
- Verify the final closing date and actual net proceeds received, as the $18.3 million figure is an estimate.
- Confirm whether the underwriters exercised the 30-day over-allotment option for an additional 666,666 shares.
- Review the full Prospectus Supplement (Registration Statement No. 333-186196) for detailed risk factors and use of proceeds.
- Check subsequent filings to confirm the 90-day lock-up period compliance for insiders.